Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Glaucoma > Kahook Dual Blade proves effective for all glaucoma severities in underserved communities
  • Glaucoma

Kahook Dual Blade proves effective for all glaucoma severities in underserved communities

Kelsey Moroz

Kahook Dual Blade (KDB) goniotomy is a highly effective and sustained treatment for reducing intraocular pressure and medication burden in Black and Afro-Latinx patients with all types and severities of glaucoma, including advanced stages, according to a study.

Researchers retrospectively reviewed surgical outcomes in 90 eyes from 90 adult patients who underwent KDB goniotomy, either alone or combined with cataract surgery. All glaucoma subtypes and severity levels were included, with follow-up extending to 20 months.

There was a sustained and significant reduction in intraocular pressure (IOP) at all time points, with mean postoperative IOP ranging from 12.9 to 13.5 mmHg—over 31% lower than baseline. Medication use also dropped by an average of 2 agents by month 20. Surgical success, defined by reduced IOP or fewer medications, was achieved in over 95% of patients throughout the study.

The authors advocate for broader use of minimally invasive glaucoma surgery (MIGS) like KDB in underserved Black and Afro-Latinx communities globally.

Reference
Ifantides C, Bejar H, Patnaik J, et al. Kahook Dual Blade Goniotomy Outcomes in the Underserved Dominican Republic Black and Afro-Latinx Population. J Clin Med. 2025;14(7):2201. doi: 10.3390/jcm14072201. PMID: 40217651.

Share

Related Content

  • Glaucoma

Glaucoma drainage devices provide meaningful IOP control in pediatric glaucoma

  • Glaucoma

Expanding the glaucoma treatment landscape with FLIGHT technology

  • Glaucoma

Geographic differences in glaucoma care raise concerns about equitable access

  • Glaucoma

Study finds significant IOP reductions with iDose TR and MIGS procedures

  • Glaucoma

EyeValve device lowers IOP and maintains control for 9 months in first-in-human study

  • Glaucoma

GLP-1 therapies may offer potential benefits in glaucoma

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon